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Abstract
Background: We previously showed microRNAs (miRNAs) in plasma are potential biomarkers for colorectal cancer
detection. Here, we aimed to develop specific blood-based miRNA assay for breast cancer detection.
Methodology/Principal Findings: TaqMan-based miRNA profiling was performed in tumor, adjacent non-tumor,
corresponding plasma from breast cancer patients, and plasma from matched healthy controls. All putative markers
identified were verified in a training set of breast cancer patients. Selected markers were validated in a case-control cohort
of 170 breast cancer patients, 100 controls, and 95 other types of cancers and then blindly validated in an independent set
of 70 breast cancer patients and 50 healthy controls. Profiling results showed 8 miRNAs were concordantly up-regulated
and 1 miRNA was concordantly down-regulated in both plasma and tumor tissue of breast cancer patients. Of the 8 up-
regulated miRNAs, only 3 were significantly elevated (p,0.0001) before surgery and reduced after surgery in the training
set. Results from the validation cohort showed that a combination of miR-145 and miR-451 was the best biomarker
(p,0.0001) in discriminating breast cancer from healthy controls and all other types of cancers. In the blind validation, these
plasma markers yielded Receiver Operating Characteristic (ROC) curve area of 0.931. The positive predictive value was 88%
and the negative predictive value was 92%. Altered levels of these miRNAs in plasma have been detected not only in
advanced stages but also early stages of tumors. The positive predictive value for ductal carcinoma in situ (DCIS) cases was
96%.
Conclusions: These results suggested that these circulating miRNAs could be a potential specific biomarker for breast
cancer screening.
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Introduction
Breast cancer is one of the three most commonly diagnosed
cancers among women, accounting for about 30% of patients [1].
Screening for breast cancer allows early stage diagnosis of the
malignancy and hence has potential to reduce mortality. In the
past decades, despite the dedication of research and resources to
the development of biomarkers for diagnosis and prognosis,
unpredictable response and development of resistance to adjuvant
therapy remain as major challenges in breast cancer management.
Although mammography diagnosis for breast cancer is the
currently used noninvasive screening tool, the cost incurred and
expertise required for mammography has hampered the wide
application of this procedure. In addition, it has limited sensitivity
in its use in young women and women with dense breasts. On the
other hand, alternative methods such as ultrasound screening has
very operator dependent sensitivity and tumor markers such as
CA15.3 and carcinoembryonic antigen (CEA) are also non-specific
and has limited sensitivity and specificity [2]. Thus, there is still a
pressing need to develop a cost-effective and accurate screening
method for this cancer.
Recently, the emergence of small non-protein-coding RNAs,
microRNAs (miRNAs), playing important roles in oncogenesis has
opened new opportunities for early cancer diagnosis [3,4].
MiRNAs are 19–25-nucleotides regulatory non-coding RNA
molecules that regulate the expressions of a wide variety of genes
by sequence-specific base pairing on the 39 untranslated regions of
the target mRNA resulting in mRNA degradation or inhibition of
translation. Evidence suggests that miRNA expression profiles can
cluster similar tumor types together more accurately than the
expression profiles of protein-coding mRNA genes [5]. Further-
more, miRNA expression signatures have been used to predict
prognosis [6,7]. Importantly, expression of some miRNAs
correlated with the molecular subtypes and with two major
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features of breast cancer (grade and ER status) [8]. As a screening
tool acceptable for general population, it would be desirable to
detect cancer accurately without resorting to an invasive
procedure. Recently, several reports have suggested that circulat-
ing miRNAs are stable and detectable in serum/plasma and the
levels of some miRNAs specifically elevated in the patients with
tongue [9], lung cancer [10], prostate cancer [11], ovarian cancer
[12], breast cancer [13,14] and colorectal cancer [15,16]. These
findings suggest that blood-based miRNAs could emerge as
revolutionary sources of biomarker for breast cancer diagnosis.
Previously, we have shown that miRNAs in plasma are promising
biomarkers for colorectal cancer detection [15]. Similarly, we here
used a systemic strategy to identify miRNAs in plasma for breast
cancer detection and utilize such miRNA biomarkers for the
development of a sensitive and specific blood-based diagnostic
assay.
Materials and Methods
Ethics Statement
The study was performed in accordance with the Declaration of
Helsinki. Written informed consent was obtained from all
participants involved in this study. This study was approved by
the Institutional Review Board of the University of Hong Kong/
Hospital Authority West Cluster and other contributing hospitals,
Hong Kong.
Study Design and Patients
A total of 260 patients who have been clinically diagnosed as
breast cancer at the time of participation were recruited between
2008 and 2010 from Queen Mary Hospital and Tung Wah
Hospital. A total of 170 normal control subjects were recruited
from Queen Mary Hospital and Tung Wah Hospital and were
pathologically confirmed not to have breast cancer and no history
of other cancers. This study is divided into three stages (Figure 1):
Marker discovery, Marker selection and training, Marker valida-
tion and Blind validation. Marker discovery: Preoperative plasma,
corresponding breast tumor and their adjacent non-tumor breast
tissues from 5 female untreated breast cancer patients were
collected. Five age-matched pathologically confirmed non-breast
cancer female normal control subjects were used as control.
MiRNA profiling was performed on (a) breast cancer plasma, (b)
normal plasma, (c) tumor, and (d) adjacent non-tumor tissue of
those patients. By comparing miRNA profiles from the 4 groups,
commonly up-regulated and down-regulated miRNAs in both
plasma and tumor were identified. Marker selection and training:
Plasma from 15 female breast cancer patients before and after 14
days after surgery were collected together with 15 pathologically
confirmed non-breast cancer control subjects. Putative miRNA
markers identified in stage I were validated on these samples. For
those up-regulated markers proceeding to marker validation, the
preoperative plasma levels of the marker must be significantly
elevated and be significantly reduced after tumor resection. Marker
Figure 1. Schematic diagram of the workflow of this study.
doi:10.1371/journal.pone.0053141.g001
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validation: Plasma was collected from a case-control group (Queen
Marry Hospital) of 170 untreated female breast cancer patients.
Plasma from 60 normal female control subjects and 40normal
male control subjects were also collected. Putative markers are
verified on these set of samples. Plasma from colorectal cancer
(CRC), esophagus cancer (EC), gastric cancer (GC), hepatocellular
carcinoma (HCC) and lung cancer (LC) patients were also
included to examine the specificity of the makers. Blind validation:
Plasma was collected from an independent group (Tung Wah
Hospital) of 70 untreated female breast cancer patients and 50
normal female subjects were collected. Tumors were staged
according to the tumor-node-metastasis (TNM) staging system of
WHO. Written informed consent was obtained from all partici-
pants involved in this study. This study was approved by the
Institutional Review Board of The University of Hong Kong/
Hospital Authority West Cluster, Hong Kong.
Samples Processing and MicroRNA Extraction
Total RNA was extracted from tissues using the TRIzolH
reagent (Invitrogen) following the manufacturer’s instructions.
Blood samples were centrifuged at 16006g for 10 minutes at 4uC,
and plasma was carefully transferred into new tubes followed by
further centrifugation at 160006 g for 10 minutes at 4uC. Total
RNA containing small RNA was extracted from 500 ml of plasma
using Trizol LS reagent (Invitrogen) and miRNeasy Mini Kit
(Qiagen, Hilden, Germany) according to the manufacturer’s
protocol with the following modifications [15]: 1 ml Trizol LS
reagent was added to 500 ml plasma samples. After phase
separation, 1.5 volume of 100% ethanol was added to the aqueous
phase and the mixture was loaded into miRNeasy column
(Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. DNase treatment was carried out to remove any
contaminating DNA (RNase-Free DNase Set, Qiagen, Hilden,
Germany). The final elution volume was 30 ml. The concentration
of all RNA samples were quantified by NanoDrop 1000
(Nanodrop).
Plasma miRNA Profiling
Profiling was performed using TaqMan Array Human Micro-
RNA Panels A and B (Applied Biosystems, Carlsbad, CA, USA)
including the respective reverse-transcription primers, PCR
primers, and TaqMan probe. For each assay, 150 ng of total
RNA extracted from plasma or tissue samples was used for the
reverse-transcription reaction with a pool of Megaplex RT primers
according to the manufacturer’s protocol. TaqMan-based qPCR
profiling was performed using TaqMan Universal PCR Master
Mix (Applied Biosystems) in ABI PRISM 7900 HT system
(Applied Biosystems) according to the manufacturer’s instructions.
Plasma miRNA Quantitative PCR
SYBR green qRT-PCR assay was used as previously described
[15]. In brief, 50 ng of plasma RNA was polyadenylated and
reverse transcribed to cDNA using miScript Reverse Transcription
kit (Qiagen). Real-time qPCR was performed using miScript
SYBR Green PCR kit (Qiagen) in ABI PRISM 7900 HT system.
The miRNA-specific forward primers sequences were designed
based on the miRNA sequences obtained from the miRBase
database. The miRNA-specific primer sequences for qPCR were
listed in Table S1. Each sample was run in duplicates for analysis.
The expression levels of miRNAs were normalized to RNU6B (U6
small nuclear RNA) as described previously [15]. Fold change of
miRNA was calculated by the equation 2–DDCt. DCt was
calculated by subtracting the Ct values of RNU6B from the Ct
values of the miRNA of interest. DDCt was then calculated by
subtracting DCt of the control from DCt of cancer.
Statistical Analysis
The significance of plasma miRNA levels was determined by
Mann-Whitney test, Wilcoxon test, x2 test or Kruskal-Wallis test
where appropriate. The sensitivity and specificity were calculated
according to the standard formulas. Multivariate logistic regression
model was established and leave-one-out cross validation to find
the best logistic model. ROC curves were established for
discriminating patients with or without breast cancer. The optimal
sensitivity and specificity from ROC curves were determined by a
commonly used method [17]. All P-values are two-sided and less
than 0.05 was considered statistically significant. All statistical
calculations were performed by GraphPad PRISM 5 software
(GraphPad Software, La Jolla, CA).
Results
Patient Characteristics
From December 2008 through September 2010, a total of 525
participants including 260 breast cancer patients, 170 normal
control subjects, 20 CRC, 20 GC, 20 EC, 15 LC, and 20 HCC
patients were recruited. Patient characteristics were summarized in
Table 1. There were no significant differences of age between
breast cancer patients and controls. The sex distribution in control
group was 40:130 (male: female).
Plasma miRNA Marker Discovery
Previously, we have developed an approach for rapid and
effective identification of tumor-derived miRNAs in plasma [15].
In this approach, the differential expression patterns between
plasma and tumor tissue samples are compared so as to rule out
plasma miRNAs predominantly derived from sources other than
breast tumor cells. Using 2-fold expression difference as a cutoff
level, 8 miRNAs (miR-16, miR-21, miR-27a, miR-150, miR-191,
miR-200c, miR-210, miR-451) up-regulated and 1 miRNA (miR-
145) down-regulated in both plasma and tumor tissues in breast
cancer patients were identified (Table S2 and S3).
Marker Selection and Training
To validate the putative markers identified from the profiling
results, plasma levels of these miRNAs were measured by qRT-
PCR assays. As described previously [15], RNU6B was used as an
internal normalization control in plasma. To prove RNU6B is a
reliable normalization control, plasma RNU6B level was evaluated
in breast cancer patients. Our data demonstrated that no
significant difference was observed in term of Ct values of RNU6B
(p = 0.75) between control (n = 100) and breast cancer samples
(n = 120) (Figure S1) suggesting that RNU6B constitutively
expressed in plasma regardless of different disease conditions.
Plasma levels of the 8 up-regulated miRNAs were validated by
qRT-PCR on the 30 plasma samples (15 breast cancer patients
and 15 controls). Our data indicated that all 9 miRNAs have
100% detection rate in plasma but only miR-16, miR-21 and
miR-451 in breast cancer plasma were significantly elevated and
plasma miR-145 level significantly lower when compared to
controls (all p-values,0.001). To further verify whether miR-16,
miR-21 and miR-451 are breast cancer-associated, their plasma
levels were quantified on the postoperative plasma of the 15 breast
cancer patients after 14 days surgical removal of the tumors. Our
result showed that plasma levels of putative miR-16, miR-21 and
miR-451 markers were significantly reduced in postoperative
samples when compared to the preoperative samples (p,0.005;
Circulating microRNAs for Breast Cancer Detection
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Figure 2) whereas no significant difference of miR-145 was
obtained between pre- and post-operative plasma samples.
Marker Validation
To further verify the discriminating power of the four miRNAs
identified for breast cancer diagnosis, plasma levels of miR-16,
miR-21, miR-145 and miR-451 were assessed on an independent
group of 270 plasma samples including 170 breast cancer patients,
60 female and 40 male normal controls. To examine whether
those markers are gender specific, plasma levels were compared
between the female and male healthy controls. Our data indicated
similar plasma levels of those markers between female and male
(Figure S2), suggesting their expressions are non-gender specific.
Our results showed that all three up-regulated miRNAs were
significantly higher in breast cancer patients than that of controls
(all p-values,0.0001; Figure 3A–C) while miR-145 plasma level
was significantly lower than that of controls (p,0.05; Figure 3D).
Receiver operating characteristic (ROC) curve analyses showed
that the ROC curve areas for miR-16 and miR-451 alone were
0.912 (95% CI 0.873-0.951) and 0.938 (95% CI 0.906-0.969),
respectively (Figure 4A and 4C) while ROC curve area for miR-21
and miR-145 alone were 0.809 (95% CI 0.74220.877) and 0.631
(95% CI 0.52320.738), respectively (Figure 4B and 4D). Although
miR-16 and miR-451 alone generated satisfactory ROC values,
we have tried different marker combinations so as to obtain the
best combination for diagnosis. Using multivariate logistic
regression analysis, the best combination (p,0.0001) for breast
cancer detection was miR-451 and miR-145. For this best marker
combination calculation, we came up with a simple equation
(22DCt) in which DCt is calculated by subtracting the Ct values of
miR-145 from the Ct values of the miR-451. As a result, we
demonstrated that such combined marker of miR-451 and miR-
145 plasma levels in breast cancer patients were significantly
discriminated not only normal control subjects but also all other
types of cancers recruited in this study (Figure 5A). Furthermore,
such combined markers yielded a ROC curve area of 0.956 (95%
CI 0.93620.978; Figure 5B). The optimal sensitivity and
specificity were 90.2% (95% CI 84.1%294.5%) was 89% (95%
CI 82.5%292.9%) in discriminating breast cancer including
benign tumors from normal control plus all other types of cancers.
Using such plasma marker, the positive predictive value was 90%
(153/170) and the negative predictive value was 94.3% (184/195).
The odds ratio for cases with combined miRNAs being associated
with cancer was 44.2 (95% CI 19.32101.1).
To examine whether the plasma levels of miR-145 and miR-
451 may be associated with tumor stages, patients stratified by
TNM staging were assessed. Of the 170 breast cancer patients,
combined plasma miR-145 and miR-451 levels did not vary
significantly across benign, DCIS and various stage of the patient’s
tumor (p= 0.32; Figure S3). However, significant differences were
Table 1. Patient characteristics.
BC
(n=185)
Healthy
(n =145)
CRC
(n=20)
EC
(n=20)
GC
(n=20)
LC
(n =15)
HCC
(n=20)
Characteristic
No. of
patients
No. of
patients
No. of
patients
No. of
patients
No. of
patient
No. of
patient
No. of
patient
Age (years)
Mean 59 58 65 66 61 65 64
Median (range) 60 (36–84) 61 (40–85) 62 (54–80) 72 (50–86) 63 (45–78) 62 (55–78) 65 (56–78)
Gender
Male – 40 10 8 8 8 9
Female 185 105 10 12 12 7 11
TNM stage (Discovery set, n = 5)
I 3 – – – – – –
III 2 – – – – – –
TNM stage (Training set, n = 15)
I 1 – – – – – –
II 7 – – – – – –
III 2 – – – – – –
TNM stage (Validation set, n = 120)
DCIS/TIS 27 – – – – – –
I 31 – – – – – –
II 34 – – – – – –
III 23 – – – – – –
IV 5 – – – – – –
TNM stage (Blind validation set, n = 45)
I 15 – – – – – –
II 20 – – – – – –
III 10 – – – – – –
BC: breast cancer; CRC: colorectal cancer; EC: esophagus cancer; GC: gastric cancer; LC: lung cancer; HCC: hepatocellular carcinoma.
doi:10.1371/journal.pone.0053141.t001
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obtained when individual tumor stage, DCIS and benign tumors
were compared with the normal controls. Unfortunately, benign
tumors cannot be distinguished from invasive breast cancer by this
plasma miRNA levels. Intriguingly, of all DCIS cases (n = 27) from
our breast cancer cohort, this combined plasma marker generated
a ROC value of 0.974 (95% CI 0.93021.02). The optimal
sensitivity and specificity were 94.1% and 98.0%, respectively, in
discriminating DCIS cases from controls (Figure S4A). When
DCIS patients were stratified into high, intermediate and low
grades, the combined plasma marker indeed elevated significantly
across DCIS grading (p,0.0001; Figure S4B). Unfortunately no
correlation between plasma miRNA levels and across DCIS
grading was obtained.
Blind Validation
We further verified our markers on a blind validation cohort.
Plasma levels of miR-145 and miR-451 were assessed on an
independent blind cohort from a different hospital of 70 female
breast cancer patients and 50 healthy controls. Our blind
validation results showed that the positive predictive values for
breast cancer were 88%. The negative predictive value of this
marker was 92%. This marker yielded ROC value of 0.931 (95%
CI= 0.886 to 0.977), optimal sensitivity was 83% (95% CI=72%
to 91%) and optimal specificity was 93% (95% CI= 81% to 98%;
Figure S5).
Discussion
In this study, we have identified significant elevation of the miR-
16, miR-21, and miR-451 and significant reduction of miR-145 in
the plasma of breast cancer patients. Intriguingly, the combination
of plasma miR-145 and miR-451 levels provided the best markers
for breast cancer prediction and yielded a ROC curve area of
96%. The optimal sensitivity was 90% and optimal specificity was
92% in discriminating breast cancer from control subjects
including all other types of cancers recruited in this study. The
odds ratio for the cases with combined miR-145 and miR-451
level being associated with breast cancer was 44.2. Thus, this
finding compares favorably with one of the best results using other
circulating biomarkers for breast cancer diagnosis [18]. In the
blind validation, the positive predictive value was 88% and the
negative predictive value was 92%. Importantly, of the 27 DCIS
cases from our breast cancer cohort, the combined plasma marker
generated surprisingly good diagnostic power with optimal
sensitivity of 94% and specificity of 98% in discriminating DCIS
cases from controls.
Figure 2. MicroRNA selection and validation by quantitative RT-PCR analysis. Changes of plasma levels of (A) miR-16, (B) miR-21, (C) miR-
451 and (D) miR-145 in breast cancer patients (n = 15) before (pre-Op) and 14 days after (14 day post-Op) surgical removal of the tumor. Expression
levels of the miRNAs (Log10 scale at Y-axis) are normalized to RNU6B. Statistically significant differences were determined using Wilcoxon tests.
doi:10.1371/journal.pone.0053141.g002
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Strikingly, we here the first time showed that the best
combination of miR-451 and miR-145 plasma levels are very
specific to breast cancer and did not elevate in all other cancer
types included in this study. Besides, elevation of plasma miRNAs
has been detected in not only advanced stages of breast cancer but
also early stages (pre-invasive stages) of breast cancer such as DCIS
suggested that this marker might be useful for early diagnosis.
Surprisingly, we obtained 97% ROC value, 94% sensitivity and
98% specificity in discriminating DCIS cases from healthy
controls. Thus, further verification is worthy to be conducted in
the future to elucidate the underlying mechanism of down-
regulated miR-145 and up-regulated miR-451 in breast cancer.
Several studies have demonstrated that miR-451 was involved
in cancer. One report found that miR-451 was significantly over-
expressed between non-relapsed and relapsed head and neck
squamous cell carcinoma patients [19]. Transfection of the
doxorubicin-resistant breast cancer cells with miR-451 resulted
in the increased sensitivity of cells to the drug, indicating that
correction of altered expression of miRNA may have significant
implications for therapeutic strategies aiming to overcome cancer
cell resistance [20]. These findings support the role of miR-451 as
a regulator of cancer proliferation and open new perspectives for
the development of effective therapies for chemoradioresistant
cancers [21]. Our findings in this study suggest that miR-451 is a
potential marker for breast cancer detection. A recent study
showed that increases in plasma miR-451 levels are caused by
haemolysis [22]. Quantification of plasma miR-451 level showed
that the level in whole blood are dominated by the miRNA
Figure 3. Large-scale validation of miR-16, miR-21, miR-451 and miR-145 on an independent group of plasma samples (n=270). Box
plot of plasma levels of (A) miR-16 and (B) miR-21 and (C) miR-451 (D) miR-145 in healthy normal (N) subjects (n = 100) and breast cancer patients
(n = 170). Expression levels of the miRNAs are normalized to RNU6B. The lines inside the boxes denote the medians. The boxes mark the interval
between the 25th and 75th percentiles. The whiskers denote the interval between the 10th and 90th percentiles. Filled circles indicate data points
outside the 10th and 90th percentiles. Statistically significant differences were determined using Mann-Whitney tests.
doi:10.1371/journal.pone.0053141.g003
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content of red blood cells and that only a fraction is derived from
plasma or PBMCs (,1%). To exclude the discrepancy in our
study, we quantified serum miR-451 and miR-145 levels from 30
breast cancer patients and 30 healthy subjects in our plasma study
cohort. Our data indeed showed that the combined miR-145 and
miR-451 levels in serum from patients were significantly higher
than that of healthy subjects (Figure S6). This data indeed suggests
that the increases in plasma miR-451 levels are not caused by
haemolysis.
Emerging studies showed that miR-145 is a putative tumor-
suppressive gene that is down-regulated in several types of tumors
[23,24] and inhibits cell growth by targeting c-Myc [25] and IRS-1
[26]. Furthermore, miR-145 is reported to target the pluripotency
factors OCT4, SOX2, and KLF4 and plays a key regulator in
human stem cells [27]. Recently, Sachdeva et al further
characterized miR-145 in different cancer cell lines and found
that miR-145 functions as a tumor suppressor in a cell type–
specific manner. This report showed that miR-145 is a tumor
suppressor affecting invasion and metastasis [28].
Although miR-16 is not the best combination of plasma markers
in this study, differential expression of miR-16 has been reported
in several cancers including leukemia, pituitary adenomas,
prostate carcinoma, lung cancer and head and neck [19,29-31].
Our results that aberrant expression of plasma miR-16 in breast
cancer patients support the notion that miR-16 is not suitable for
normalization. Thus, the use of miR-16 as an internal normali-
zation control for miRNA quantitation [32] in clinical specimens
such as whole blood is still questionable.
Compared with other studies of miRNAs in diagnosing breast
cancer [18,33,34], our study is unique because we identified a
combination of miRNA markers which are very specific to breast
cancer only, not other cancers such as gastric, lung and HCC.
Interestingly, these plasma levels were significantly decreased in
lung cancer when compared with breast cancer and even normal
control. This may be probably because miR451 was recently
Figure 4. ROC curve analysis using (A) plasma miR-16, (B) plasma miR-21, (C) plasma miR-451 (D) miR-145 for discriminating breast
cancer from normal subjects.
doi:10.1371/journal.pone.0053141.g004
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found to be one of the most down-regulated miRNAs in non-small
cell lung carcinoma (NSCLC) tissues [35]. Thus, further study on
plasma miR-451 levels in NSCLC might provide clues on
potential biomarker for lung cancer diagnosis. Furthermore, these
miRNAs identified in our study are also useful as a diagnostic
marker for early stage of cancer, DCIS. Our finding that
differential expression signatures in plasma with only two miRNAs
could discriminate breast cancer from normal subjects raises the
possibility of using such marker to develop a blood-based screening
test for breast cancer in the future. Furthermore, circulating
miRNA as a diagnostic marker has advantages over circulating
mRNA. Unlike screening for large number of RNA expression, a
modest number of miRNAs might be sufficient to differentiate
cancers from normal. Unlike plasma RNAs, miRNAs in plasma
remain largely intact and have been proven to be more stable for
detection [11,36].
Although our results are promising, several limitations in this
study are addressed: (i) as the sample size is still small, further
validations in large cohorts or in different ethnic groups are
recommended; (ii) it is uncertain whether this plasma miRNA
elevation is specific for certain subtypes of breast cancer, and
whether such marker can be used to differentiate sporadic from
familial types such as BRCA mutation carriers. Thus, additional
studies are necessary to compare their plasma levels with different
subtypes; (iii) it is desirable to examine whether such plasma
miRNA change in patients undertaking various treatments.
Nevertheless, it is worthy in the future to identify novel plasma
miRNAs or non-coding RNAs using next-generation sequencing
technologies.
In conclusion, elevation of miR-16, miR-21 and miR-451 in
plasma of breast cancer patients has been reported in this study.
Strikingly, we are the first to demonstrate that reduction of plasma
miR-145 level occurred in breast cancer patients. The best
combination of plasma markers miR-145 and miR-451 in our
plasma quantitative assay makes a very promising and specific
breast cancer screening test possible. Although the testing with
these markers reach sensitivity and specificity .90% for breast
cancer prediction, the positive predictive value was around 90%
and the negative predictive value was around 92%, a combination
of other potential markers using this plasma quantitation may
further enhance the discriminating power of this test in the future.
Supporting Information
Figure S1 Box plot of RNU6B Ct values in the plasma
from Normal control and breast cancer (BC) patients.
The lines inside the boxes denote the medians. The boxes mark
the interval between the 25th and 75th percentiles. The whiskers
denote the interval between the 10th and 90th percentiles. Filled
circles indicate data points outside the 10th and 90th percentiles.-
Statistically significant differences were determined using Mann-
Whitney test. NS, non-significant.
(TIF)
Figure S2 Box plots of plasma levels of miR-16, miR-451
and miR-21 in female (F, n=60) and male (M, n=40)
healthy subjects. Expression levels of the miRNAs (Log10 scale
at Y-axis) are normalized to RNU6B. Statistically significant
differences were determined using Mann-Whitney test. NS, non-
significant.
(TIF)
Figure S3 Box plot of combined plasma miR-145 and
miR-451 levels across stage of breast cancer patients.
Expression levels of the miRNAs (Log10 scale at Y-axis) are
calculated by the equation 2 -deltaCt. deltaCt was calculated by
subtracting the Ct values of miR-145 from the Ct values of the
miR-451. The lines inside the boxes denote the medians. The
boxes mark the interval between the 25th and 75th percentiles.
The whiskers denote the interval between the 10th and 90th
percentiles. Filled circles indicate data points outside the 10th and
90th percentiles. Statistically significant differences were deter-
mined using Mann-Whitney tests.
(TIF)
Figure S4 (A) ROC analysis using combined plasma miR-145
and miR-451 for discriminating DCIS cases from normal subjects.
(B) Box plots of combined plasma levels of miR-145 and miR-451
in various DCIS graded patients. Expression levels of the miRNAs
Figure 5. Large-scale validation of combined plasma miR-145
and miR451. (A) Box plot of combined plasma miR-145 and miR-451
levels in patients of breast cancer (BC), healthy normal (N), colorectal
cancer (CRC), esophagus cancer (EC), gastric cancer (GC), hepatocellular
carcinoma (HCC) and lung cancer (LC). Expression levels of the miRNAs
(Log10 scale at Y-axis) are calculated by the equation 2-DCt. DCt was
calculated by subtracting the Ct values of miR-145 from the Ct values of
the miR-451. The lines inside the boxes denote the medians. The boxes
mark the interval between the 25th and 75th percentiles. The whiskers
denote the interval between the 10th and 90th percentiles. Filled circles
indicate data points outside the 10th and 90th percentiles. Statistically
significant differences were determined using Mann-Whitney tests. (B)
ROC analysis using combined plasma miR-451 and miR-145 for
discriminating breast cancer from normal subjects and other cancers.
doi:10.1371/journal.pone.0053141.g005
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(Log10 scale at Y-axis) are calculated by the equation 2 -deltaCt.
deltaCt was calculated by subtracting the Ct values of miR-145
from the Ct values of the miR-451.Statistically significant
differences were determined using Mann-Whitney test.
(TIF)
Figure S5 ROC analysis using combined plasma miR-145 and
miR-451 for discriminating BC cases from normal subjects in the
blind validation.
(TIF)
Figure S6 Box plot of combined serum miR-145 and
miR-451 levels from Normal control and breast cancer
(BC) patients. Expression levels of the miRNAs (Log10 scale at
Y-axis) are calculated by the equation 2 -deltaCt. DeltaCt was
calculated by subtracting the Ct values of miR-145 from the Ct
values of the miR-451. The lines inside the boxes denote the
medians. The boxes mark the interval between the 25th and 75th
percentiles. The whiskers denote the interval between the 10th and
90th percentiles. Filled circles indicate data points outside the 10th
and 90th percentiles. Statistically significant differences were
determined using Mann-Whitney test.
(TIF)
Table S1 MiRNA-specific primer sequences for qRT-PCR.
(DOC)
Table S2 The list of upregulated miRNAs (change .2 fold as a
cutoff level) identified using real-time PCR based miRNA profiling
arrays in plasma and biopsy samples of 5 breast cancer patients
compared to 5 healthy controls. Highlighted in red are the
markers up-regulated in both plasma and breast cancer tumors.
(DOC)
Table S3 The list of downregulated miRNAs (change .2 fold as
a cutoff level) identified using real-time PCR based miRNA
profiling arrays in plasma and biopsy samples of 5 breast cancer
patients compared to 5 healthy controls. Highlighted in red are the
markers down-regulated in both plasma and breast cancer tumors.
(DOC)
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